2024-09-10 - Analysis Report
## Gilead Sciences, Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing life-saving therapies for patients with serious diseases.

**Performance Analysis:**

**1.  Performance vs. S&P 500 (VOO):**

*   GILD's cumulative return is 14.01%, while VOO's cumulative return is 81.34%.
*   The difference in returns is -67.33%, which places GILD at the 22.39% percentile of its historical performance relative to VOO (where 100% is the highest). This suggests that GILD has significantly underperformed the market over the period analyzed.

**2.  Recent Price Movement:**

*   **Closing Price:** $78.72
*   **5-day Moving Average:** $79.06
*   **20-day Moving Average:** $76.36
*   **60-day Moving Average:** $72.74

This indicates a short-term upward trend, with the closing price above all three moving averages. However, the relatively small difference between the 5-day and 20-day moving averages suggests a potential consolidation phase.

**3.  Technical Indicators:**

*   **RSI:** 81.67 - This is considered overbought, indicating potential for a pullback in the near future.
*   **PPO:** 0.15 - This suggests a positive momentum in the price, although the relatively low value suggests a moderate momentum.
*   **Delta_Previous_Relative_Divergence:** 1.41 - This indicates a recent short-term upward trend, with the current price outperforming the previous relative divergence.
*   **Expected Return:** 19.61% - This represents the estimated maximum 5-year return based on current investment.

**4.  Recent Earnings and Outlook:**

| Date       | EPS      | Revenue     |
|------------|----------|-------------|
| 2024-08-08 | 1.29     | 6.95 B$     |
| 2024-05-08 | -3.34    | 6.69 B$     |
| 2023-11-07 | 1.75     | 7.05 B$     |
| 2023-08-04 | 0.84     | 6.60 B$     |
| 2024-08-08 | 0.84     | 6.60 B$     |

**Analysis:**

*   The most recent earnings report (2024-08-08) showed an EPS of 1.29, which was above analysts' expectations. 
*   Revenue for the quarter also surpassed expectations.
*   However, the company faces challenges due to competition and patent expirations for key products.

**Overall Analysis:**

GILD's recent performance has been mixed, with strong earnings results but continued underperformance compared to the broader market.  The technical indicators suggest potential for a near-term pullback despite positive momentum.  While the company faces challenges, its robust earnings performance and positive outlook could be bullish factors.

**Recommendation:**

Given the current situation, investors should monitor GILD closely. Further analysis of its long-term growth prospects, including future product launches and market competition, is necessary to make informed investment decisions.  While the company's recent earnings results are encouraging, the high RSI and underperformance relative to the market suggest caution.  

**Disclaimer:** This analysis is for informational purposes only and does not constitute financial advice. Always consult with a qualified financial professional before making any investment decisions. 
